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Abstract
Background: Doxazosin and its role as an antihypertensive agent have come under recent
scrutiny as a result of the early termination of that treatment arm in ALLHAT. It is unclear why the
cardiovascular (CV) event rate in this randomized, controlled trial (RCT), especially heart failure,
is higher in those treated with a doxazosin-based regimen than with a chlorthalidone based-
regimen. There has been little work in the past to summarize information on peripheral alpha-1
antagonists that may be helpful in evaluating the results of this randomized controlled trial.
Methods: Using Medline and the Cochrane databases, we performed a comprehensive review of
the literature on the use of peripheral alpha-1 antagonists as antihypertensive agents, focusing on
available information that could explain the excess cardiovascular events observed in the
Antihypertensive and Lipid-Lowering Treatment to prevent Heart Attack Trial (ALLHAT).
Results: Minimal data were available concerning the effects of peripheral alpha-1 antagonists on
CV endpoints. A multitude of short-term studies-ranging from small observational studies to short-
term moderate-sized RCTs – focused on safety, efficacy, and tolerability, and some studies
investigated the physiologic effects of these agents. These previously reported studies reveal
associations with weight gain, fluid retention, and neurohormonal changes among various
populations of those treated with peripheral alpha-1 antagonists.
Conclusion: These findings suggest several possible mechanisms by which doxazosin may be
inferior to low-dose diuretics as antihypertensive therapy for the prevention of heart failure.
Background
With the publication of the Antihypertensive and Lipid-
Lowering Treatment to prevent Heart Attack Trial (ALL-
HAT), the role of peripheral alpha-1 antagonists in the
treatment of hypertension has become controversial. The
doxazosin arm of ALLHAT was stopped early, due to a
doubling of the incidence of congestive heart failure in
this group, as compared to the low-dose chlorthalidone
arm [1]. Prior to this publication, there had been no obvi-
ous suggestion of a mechanism by which peripheral al-
pha-1 antagonists in general or doxazosin in particular
would be inferior to chlorthalidone or would specifically
cause CHF. Because ALLHAT is an active-control trial, no
inferences can be made on whether this increased inci-
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dence of CHF results from a harmful effect of doxazosin,
a beneficial effect of chlorthalidone, or both. Nonetheless,
there has been a large body of literature dedicated to the
positive effects of peripheral alpha-1 antagonists on surro-
gate endpoints such as cholesterol levels and tolerability.
In light of the results of ALLHAT, we performed a review
of the literature on doxazosin, terazosin, and prazosin.
Methods
Medline and the Cochrane databases were used to identify
English-language papers on peripheral alpha-1 antago-
nists in studies targeting cardiovascular endpoints, back-
ground physiologic literature, or any studies suggesting
mechanisms leading to an inferior performance in cardio-
vascular endpoints. Medline was searched from 1966 to
the present with the key words "doxazosin," "prazosin,"
"terazosin," "adrenergic alpha-antagonists," or "alpha
blocker." The search was then limited to clinical trials that
had "hypertension" as a key word. Studies were included
in our review if they addressed either one or a combina-
tion of the three agents as the main focus in the context of
hypertension therapy and if they in some way addressed
the outcomes of interest noted above. Relevant data from
these studies are reported descriptively. Other relevant ref-
erences were acquired from bibliographic searches.
Results
The initial search in May, 2001 retrieved 844 citations
from Medline. No additional studies were revealed in the
Cochrane database. Of the Medline citations, 226 related
to the use of prazosin, terazosin, or doxazosin in the con-
text of antihypertensive therapy. The articles were grouped
into descriptive categories created from useful summary
topics or from recurrent themes noted in the trials that
were pertinent to the outcomes of interest. These trial-
based categories and the final count of the reported stud-
ies included: use in hypertension and prostatism-2 stud-
ies; weight and fluid status-14 studies; neurohormonal
effects-5 studies; and epidemiological and clinical trial
data-1 study.
Use in Hypertension and Prostatism
Evidence suggests that alpha-1 antagonists are frequently
prescribed for hypertension, but there are few published
data concerning the prevalence of the routine use of pe-
ripheral alpha-1 antagonists, the prevalence according to
co-morbid conditions such as benign prostatic hypertro-
phy and the usual duration of therapy. In the sixth report
of the Joint National Committee on Prevention, Detec-
tion, Evaluation, and Treatment of High Blood Pressure
(JNC VI), peripheral alpha-1 antagonists are recommend-
ed not only as second-line anti-hypertensive therapy after
low-dose diuretics and beta blockers, but also for specific
indications such as therapy in men with hypertension and
prostatism [2]. Alpha-1 antagonists represent effective
therapy for prostatism, and fifty percent of men have his-
tologic evidence of BPH by 60 years of age [3,4]. The Na-
tional Ambulatory Medical Care Survey reported that the
number of people on any type of peripheral alpha-1 an-
tagonist in 1995 was approximately 6 to 7% of those with
hypertension [5]. About 80% of surveyed physicians
would choose these drugs as a first-line blood pressure
agent for patients with hypertension and symptoms of
BPH [6].
Weight and Fluid Status
Peripheral alpha-1 antagonists were consistently associat-
ed with fluid retention. A 1984 study of prazosin reported
by Bauer revealed increases in plasma volume, interstitial
fluid volume, and extracellular fluid volume following
both short-term and long-term therapy [7]. In this study
of 14 hypertensive men, there was a significant 1.4 L aver-
age increase in ECFV, with a 200 mL average increase in
plasma volume (measured with radioisotopic assays) that
occurred within 3–6 weeks of initiation, lasted during 5 to
6 months of chronic therapy, and was still present during
a two-week washout period. There was no weight change
in that study, but two other studies demonstrated both an
increase in weight as well as laboratory changes consistent
with volume expansion for prazosin [8,9]. Bauer and his
colleagues suggested that a net increase in total body sodi-
um from an acute renal effect of prazosin was offset by a
decrease in actual body weight. They also demonstrated
that the fractional excretion of sodium was unchanged
during treatment, and further suggested that the acute
changes were followed by chronic sodium homeostasis
and maintenance of the increased total body sodium.
The VA Cooperative Study on Antihypertensive agents was
a double-blind, randomized controlled trial comparing
atenolol, captopril, clonidine, diltiazem, hydrochlorothi-
azide, prazosin, and placebo for differences in antihyper-
tensive efficacy in 1,105 men who had mild diastolic
hypertension [10]. A highly significant weight gain of 1
kilogram was observed at 8 weeks with prazosin com-
pared to baseline (p < .001), and this gain was also statis-
tically significant when compared to the 8-week weight
changes in all other groups that had experienced either
weight loss or no mean weight change (p < 0.05). The pra-
zosin arm had the highest rate of adverse effects, leading
to discontinuation of treatment. The termination rate of
13.8% was higher than the termination rate from adverse
effects for clonidine (10.1%), and significantly higher
than the rates for captopril (4.8%), atenolol (2.2%), or
hydrochlorothiazide (1.1%) [11]. The number of men
treated with prazosin decreased from 62 at the beginning
of the trial to 28 by the end. The average weight gain of 0.5
kilograms from baseline was no longer statistically signif-
icant at one year of therapy when compared to the origi-
nal baseline weight or the other therapies.Current Controlled Trials in Cardiovascular Medicine 2002, 3 http://cvm.controlled-trials.com/content/3/1/7
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Safety and tolerability trials with terazosin have shown
similar results (Table 1). Patients treated with terazosin
tended to gain about 1 kilogram from baseline on active
therapy during these trials, and those on placebo therapy
lost weight. Two of the randomized trials included a phase
for withdrawal from active therapy, with weight informa-
tion reported by Ruoff [12]. Withdrawal from active ther-
apy was associated with a loss of 1.3 kilograms.
Doxazosin has also been associated with volume expan-
sion. A physiology study reported by Lund-Johansen dem-
onstrated a plasma volume fluid expansion of about 10%
when compared to baseline values [13]. Larger rand-
omized controlled trials have also consistently demon-
strated that patients treated with doxazosin gain weight,
as summarized in Table 2. While patients treated with
doxazosin tend to gain weight, patients on placebo thera-
py lost weight. The Treatment of Mild Hypertension Study
(TOMHS) trial is a notable exception for the trend to-
wards weight gain [14]. All five treatment groups and the
placebo group received intensive dietary counseling
aimed at weight loss, and all groups lost weight without
significant differences between trial arms.
Neurohormonal and Cellular Effects
Physiologic studies with small numbers of participants are
by nature underpowered to detect meaningful population
differences, but may provide a starting point when such
data are not available. Peripheral alpha-1 antagonists
were associated with perturbations in neurohormonal lev-
els in various studies. In particular, peripheral alpha-1 an-
tagonists are associated with an increase in plasma
norepinephrine in diverse patient populations, as sum-
marized in Table 3. This table reflects increases in nore-
pinephrine in normotensive patients, hypertensive
patients, and patients with chronic congestive heart fail-
ure from a variety of these small studies.
Several lines of evidence suggest that elevated catecho-
lamine levels are cardiotoxic [15]. Elevated plasma nore-
pinephrine levels are hypothesized to cause direct
myocardial damage through many mechanisms, which
may be amplified by concomitant alpha-1 blockade. In
rats, norepinephrine stimulates apoptosis, which is medi-
ated through beta receptors [16]. In addition, alpha-1 car-
diac receptors inhibit this response in rat myocytes [17].
The increased concentration of norepinephrine leading to
cardiac beta receptor stimulation combined with alpha-1
receptor inhibition may lead to increased apoptosis in
myocytes.
Other hormones that are associated with cardiovascular
disease are affected by peripheral alpha-1 antagonists. En-
dothelin-1 is a vascular hormone, which may play a role
in the generation and maintenance of heart failure [18]. In
hypertensive patients, doxazosin lowers von Willebrand
factor commensurate with blood pressure, but it does not
Table 1: Weight Change with Terazosin
Study Type N in study Weight Change in Kg/
Number on therapy
Significance
Total Men Women
n ∆ n ∆ n ∆
RCT
Deger [8] 174 100 49 +1.4 51 +1.2 p < .001 from baseline
Sperzel [27] 865 569 438 +0.9 131 +0.4 p < .05 against placebo
Observational*
Luther [28]† 364 -- 0 to +1.4 No statistical comparison
Mersey [29] 226 -- 0 to +1.4 No statistical comparison
Withdrawal
 from therapy‡
Ruoff [12] 27 13 -1.3 'statistically significant' from baseline in both
Ruoff [12] 69 32 19 -1.6 13 -1.6
*Observational studies were open label, multicenter, follow-up studies of hypertensive patients on terazosin. †Trial demonstrated significant 
hemodilution by laboratory exams. ‡Two different RCTs are reported, in which responders to terazosin were randomized to withdrawal of ther-
apy and monitored.Current Controlled Trials in Cardiovascular Medicine 2002, 3 http://cvm.controlled-trials.com/content/3/1/7
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lower high levels of endothelin-1 while atenolol does
[19].
Other mechanisms for cellular injury have been suggest-
ed. Hooper proposed that peripheral alpha-1 antagonists
alter cellular repair mechanisms, possibly causing cardiac
damage. He noted that prazosin blocks heat shock protein
expression in myocardium, and it has been hypothesized
that this may leave myocardium more vulnerable to injury
[20].
Epidemiological and Clinical Trial Data
Between 1966 and 2001, there were 188 published cardi-
ovascular randomized controlled trials related to the treat-
ment of hypertension with the use of peripheral alpha-1
antagonists. Among these, only ALLHAT specifically as-
sessed differences in cardiovascular endpoints resulting
from control of hypertension with a peripheral alpha-1
antagonist. Most of these trials focused on surrogate end-
points such as equivalence of blood-pressure reduction
and effects on cholesterol. Other studies focused on toler-
ability and pharmacology. There are no case control, co-
hort, or other studies that analyzed the impact of these
Table 2: Weight Change with Doxazosin
Study Number of
 subjects
Type of
 Study
Weight change in kilograms
  (number on therapy)
Doxazosin Placebo Other therapy p-value¶
Ames [30] 147 RCT +1.5 (n = 73) -0.2 kg (n = 74) 'significant'
ABC trial [31]* 191 RCT + 1.16 (n = 96) -0.04, atenolol (n = 95) p = .019
Ott [32] 126 RCT +2.0 (n = 63) + 0.9, atenolol (n = 63) NS
Torvik [33] 172 RCT + 0.04 ± 0.2 (n = 58) -1.18 ± 0.29 (n 
= 57)
+0.21 ± 0.2, prazosin (n = 57) p < .001 for 
treated groups
TOMHS [34]† 902 RCT -3.1 (n = 134) -3.9, chlorthalidone (n = 136) NS
Comparison made by intention to treat; patients on doxazosin withdrawing from the ABC study (n = 39) had a mean weight gain of 2.21 kg. †Trial 
included diet therapy for weight loss. ¶p for comparison between groups and not from baseline.
Table 3: Increase in Norepinephrine (NE) with Peripheral Alpha-1 Antagonists
Study population Reference Study design Drug N Findings
Normotensive Takata [35] observational doxazosin 8 Trend towards increase in NE with therapy;
 60% decrease in NE after withdrawal of
 therapy
Hypertensive Izzo [36] comparative prazosin 8 50% increase in NE; 0.9 kg wt gain
captopril 8 12% decrease in NE, 0.82 kg wt loss,
 p < 0.01 for comparison
CHF Colucci [37] observational prazosin 10 Increase in NE from 145 ± 133* to
 481 ± 376 with therapy
Stein [38] observational prazosin 8 Increase in NE from 276 ± 347 to
 521 ± 130 with therapy
Markham [39] RCT prazosin 25 Treatment group NE increased from
 790 ± 280 to 1413 ± 1030 after four weeks of
 therapy; 
placebo group was 749 ± 315 at baseline and 
772 ± 596 at four weeks, p for difference at four weeks = 
0.08.
* Values for NE are given in pg/mL.Current Controlled Trials in Cardiovascular Medicine 2002, 3 http://cvm.controlled-trials.com/content/3/1/7
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agents on cardiovascular endpoints. Using data from oth-
er trials may offer a partial framework for the interpreta-
tion of newer findings.
ALLHAT demonstrated a highly statistically significant,
near doubling in the incidence of heart failure in the dox-
azosin arm compared to heart failure occurrences in the
chlorthalidone arm. Although there was no difference in
the primary outcome of CHD or the secondary outcome
of total mortality, there were small but statistically signif-
icant increases in the secondary outcomes of angina (RR
1.16, 95% CI 1.05–1.27) and stroke (RR 1.19, 95% CI
1.01–1.40). Since ALLHAT is a comparative trial, we know
that doxazosin is associated with more adverse cardiovas-
cular outcomes than low-dose chlorthalidone, but we do
not know how doxazosin might compare with placebo.
The SHEP trial, however, does provide a comparison be-
tween chlorthalidone and placebo therapy for a reference
point of heart failure, although the study populations
have different demographic and blood pressure distribu-
tions [21]. The SHEP trial included 4,736 people aged 60
and older who had a systolic blood pressure of 160 to 219
mmHg and a diastolic blood pressure of less than 90 mm-
Hg. Subjects were randomized to low-dose diuretics or
placebo, and were followed for an average of 4.5 years for
major CV events. Comparisons between those rand-
omized to active therapy and those on placebo demon-
strated nearly a 50% reduction in fatal and nonfatal heart
failure events (RR 0.51, 95% CI 0.37–0.71). The rates of
CHF in SHEP participants treated with diuretics and pla-
cebo were 5 and 10 per 1,000 person-years, respectively.
In comparison, the rates of CHF in ALLHAT participants
treated with diuretics and doxazosin were 10 and 20 per
1,000 person-years, respectively. If low-dose chlortha-
lidone has a similar risk reduction in the ALLHAT popula-
tion, and halves the incidence of clinical heart failure
events compared to no therapy, the effect of doxazosin
would be comparable to that of the placebo arm in the
SHEP trial.
Conclusions
The report of the doxazosin arm termination in ALLHAT
was published in April, 2000. At that time, the results of
the ALLHAT trial were unexpected, given the potential as-
sociation between high dose diuretics and the risk of sud-
den death [22], and the favorable effect of peripheral
alpha-1 antagonists on lipid profiles [14]. Comparing
data from other studies suggests the possibility that the
beneficial effects of peripheral alpha-1 antagonists for
lowering blood pressure may be nullified by a negative ef-
fect, or that other antihypertensives have positive actions
beyond their antihypertensive effects. Those treated with
doxazosin in ALLHAT had a mean blood pressure that was
2 to 3 mmHg higher than the mean blood pressure of
those treated with chlorthalidone. Based on Framingham
Heart Study logistic regression coefficients, this 2 to 3
mmHg difference in systolic blood pressure is associated
with an increased relative risk of only 1.06 to 1.09 [23].
From available data, it appears that this average difference
in systolic blood pressure is not large enough to double
the average incidence of CHF.
The literature suggests several mechanisms by which pe-
ripheral alpha-1 antagonists in general and doxazosin in
particular might prove inferior to other types of antihyper-
tensive therapy. They are associated with a mild volume
expansion, which may precipitate the clinical presenta-
tion of heart failure in those with subclinical disease. If
this is the mechanism responsible for increasing the inci-
dence of CHF in the ALLHAT trial, it would be consistent
with the early divergence of the Kaplan-Meier curves in
that study.
Peripheral alpha-1 antagonists also cause neurohormonal
changes during chronic therapy. The long-term ramifica-
tions of these changes for patients being treated for hyper-
tension are not known. These drugs appear to cause
increases in norepinephrine, and this increase may nullify
the beneficial effect of lowered blood pressure on the oc-
currence of CHF. Not only are increased plasma catecho-
lamines a central feature in heart failure, they are now a
recommended target for effective life-prolonging therapy
[24–26].
Given that doxazosin is not as effective as chlorthalidone
in reducing the cardiovascular complications of hyperten-
sion, several questions remain. There is still a paucity of
information regarding the absolute risk reduction for clin-
ical heart failure or other cardiovascular events afforded
by peripheral alpha-1 antagonists in a variety of popula-
tions. Differentiation of the mechanism for reduced pro-
tection compared to diuretics would be interesting but
difficult to accomplish. For heart failure in particular, the
increase in symptomatic episodes of CHF may be due to
hemodynamic effects of doxazosin unmasking incipient
heart failure, direct myocardial injury, or both. Chronic
volume loading may not only unmask subclinical ven-
tricular dysfunction, but may possibly contribute to wors-
ening ventricular function over time.
Whatever mechanisms were responsible for the heart fail-
ure findings in ALLHAT, the results support the current
national recommendations to use low-dose diuretics or
beta-blockers as first line agents for the pharmacologic
treatment of uncomplicated hypertension.
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